Salivary and serum nitric oxide synthase, macrophage inflammatory protein 1 alpha and macrophage migration inhibitory factor levels in periodontal disease

被引:0
|
作者
Oner, Fatma [1 ]
Onat, Faruk Cagri [2 ]
Karasu, Yerda Ozkan [2 ,3 ]
机构
[1] Bahcesehir Univ, Fac Dent Med, Dept Periodontol, Istanbul, Turkiye
[2] Ataturk Univ, Fac Dent & Med, Dept Periodontol, Erzurum, Turkiye
[3] Ataturk Univ, Fac Dent Med, Dept Periodontol, TR-25200 Yakutiye Erzurum, Turkiye
关键词
Gingivitis; iNOS; MIP-1; alpha; MIF; Periodontitis; PERI-IMPLANT DISEASES; 2017 WORLD WORKSHOP; CONSENSUS REPORT; MIP-1-ALPHA; EXPRESSION; BIOMARKERS; MIF; CLASSIFICATION; CONTRIBUTES; IMMUNITY;
D O I
10.1016/j.heliyon.2024.e25888
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: Periodontal disease is multifactorial inflammatory disease involving both gingivitis and periodontitis. Inducible nitric oxide synthase (iNOS), macrophage inflammatory protein 1 alpha (MIP-1 alpha) and macrophage migration inhibitory factor (MIF) are mediators contributing to the progression of periodontal diseases with distinct functions. The aim of this study is to evaluate the local and systemic iNOS, MIP-1 alpha and MIF concentrations in patients having periodontal disease with different severities. Design: The study was conducted on 88 individuals equally divided into four groups; 1) Periodontally Healthy 2) Gingivitis 3) Stage I-II Periodontitis 4) Stage III-IV Periodontitis. Saliva and serum samples were obtained from each individual and then periodontal examinations were performed. Plaque and bleeding on probing indexes, probing depths and clinical attachment levels were measured on each tooth to determine the periodontal status. Concentrations of iNOS, MIP-1 alpha and MIF were measured with enzyme -linked immunosorbent assay. Results: Patients with stage I-II and stage III-IV periodontitis had more iNOS levels than periodontally healthy people in serum and saliva (p <= 0,001 for serum; p < 0,05 for saliva). Stage III-IV periodontitis group had significantly more serum-iNOS levels than that in gingivitis group (p = 0,005). When compared with periodontally healthy individuals, MIP-1 alpha levels in stage III-IV periodontitis patients were measured significantly more in saliva; (p = 0,016) but less in serum (p = 0,006) samples. More serum-MIF concentrations were observed in stage I-II periodontitis groups than that in periodontally healthy individuals (p < 0,05). Conclusion: Increased salivary and serum iNOS and serum-MIF levels in different stages of periodontitis suggest that these molecules might be involved in periodontal disease pathogenesis. Also, oral microenvironment may stimulate the enhanced MIP-1 alpha concentration in advanced periodontitis cases.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease
    Lee, T. J.
    Chun, J. K.
    Yeon, S. I.
    Shin, J. S.
    Kim, D. S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2007, 36 (03) : 222 - 225
  • [2] Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor
    Nicoletti, Alessandra
    Fagone, Paolo
    Donzuso, Giulia
    Mangano, Katia
    Dibilio, Valeria
    Caponnetto, Salvatore
    Bendtzen, Klaus
    Zappia, Mario
    Nicoletti, Ferdinando
    CYTOKINE, 2011, 55 (02) : 165 - 167
  • [3] Serum levels of macrophage migration inhibitory factor in various types of glomerulonephritis
    Honda, K
    Nishihira, J
    Nitta, K
    Kobayashi, H
    Uchida, K
    Kawashima, A
    Yumura, W
    Nihei, H
    NEPHRON, 2000, 86 (01): : 91 - 92
  • [4] Serum macrophage migration inhibitory factor levels in Hashimoto’s thyroiditis
    Ayman Abd Elrahman
    Nagwa S. Said
    Azza Moustafa
    The Egyptian Journal of Internal Medicine, 2019, 31 (1) : 31 - 37
  • [5] New therapeutic target in inflammatory disease: macrophage migration inhibitory factor
    Morand, EF
    INTERNAL MEDICINE JOURNAL, 2005, 35 (07) : 419 - 426
  • [6] Elevated serum levels of macrophage migration inhibitory factor(MIF) in patients with Behcet's disease
    Kim, S
    Kim, S
    Kim, H
    Park, M
    Yoon, C
    Kim, W
    Lee, S
    Park, S
    Cho, C
    Kim, H
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 321 - 322
  • [7] Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma
    de Souza, Mariana Barbosa
    Curioni, Otavio Alberto
    Kanda, Jossi Ledo
    De Carvalho, Marcos Brasilino
    ONCOLOGY LETTERS, 2014, 8 (05) : 2267 - 2275
  • [8] Impact of Macrophage Migration Inhibitory Factor Gene Polymorphisms and Serum Macrophage Migration Inhibitory Factor Levels on Pulmonary and Spinal Tuberculosis Susceptibility: A Pooled Analysis
    You, Shu-ying
    Zeng, Xiang-bo
    Li, Na
    Yang, Shi-kun
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2022, 26 (09) : 430 - 442
  • [9] Macrophage migration inhibitory factor in cardiovascular disease
    Zernecke, Alma
    Bernhagen, Juergen
    Weber, Christian
    CIRCULATION, 2008, 117 (12) : 1594 - 1602
  • [10] Serum macrophage migration inhibitory factor and leptin levels in patients with acute trichinellosis
    Sari, I.
    Kozaci, L. D.
    Akar, S.
    Birlik, M.
    Kavak, T.
    Akkoc, N.
    Onen, F.
    FEBS JOURNAL, 2006, 273 : 271 - 271